Patents Assigned to Grunenthal GmbH
  • MULTIPARTICULATE ORAL DOSAGE FORM PROVIDING PROLONGED RELEASE OF TAPENTADOL
    Publication number: 20180369151
    Abstract: The invention relates to an oral pharmaceutical dosage form comprising a plurality of coated particles, wherein said coated particles comprise a core which comprises a Tapentadol component and which is coated with a controlled release coating material, wherein the controlled release coating material comprises a lubricant component and a polymer component, wherein the polymer component comprises one or more cellulose ethers and/or one or more acrylates, and wherein the pharmaceutical dosage form provides controlled release of the Tapentadol component.
    Type: Application
    Filed: May 29, 2018
    Publication date: December 27, 2018
    Applicant: GRÜNENTHAL GMBH
    Inventors: Marc SCHILLER, Ulrich REINHOLD, Ulrike BERTRAM, Wolfgang PRANGE, Anika-Anina PHILIPP, Stefanie STRAUB, Annette GRAVE, Norbert POELLINGER
  • Tamper-resistant tablet providing immediate drug release
    Publication number: 20180369149
    Abstract: The invention relates to a tamper-resistant tablet comprising (i) a matrix material in an amount of more than one third of the total weight of the tablet; and (ii) a plurality of particulates in an amount of less than two thirds of the total weight of the tablet; wherein said particulates comprise a pharmacologically active compound and a polyalkylene oxide; and form a discontinuous phase within the matrix material; and method of using said tablet to treat pain and other conditions.
    Type: Application
    Filed: August 30, 2018
    Publication date: December 27, 2018
    Applicant: Grünenthal GmbH
    Inventors: Sebastian Schwier, Marcel Haupts, Udo Rüttgers, Lutz Barnscheid, Jana DENKER
  • TITRATION OF CEBRANOPADOL
    Publication number: 20180369199
    Abstract: The invention relates to Cebranopadol for use in the treatment of pain, wherein Cebranopadol is administered according to an administration regimen comprising (i) a first administration interval, which lasts for at least 2 consecutive days, wherein a first daily dose of Cebranopadol is administered on every day of the first administration interval; and (ii) a second administration interval, which lasts for at least 2 consecutive days and directly follows the first administration interval without interruption, wherein a second daily dose of Cebranopadol is administered on every day of the second administration interval; wherein the first daily dose of Cebranopadol is lower than the second daily dose of Cebranopadol.
    Type: Application
    Filed: August 29, 2018
    Publication date: December 27, 2018
    Applicant: GRÜNENTHAL GMBH
    Inventors: Shaonan WANG, Chiara PIANA, Roberta BURSI
  • Pharmaceutical salts
    Patent number: 10160719
    Abstract: The invention relates to pharmaceutical salts comprised of a pharmaceutical active substance and of at least one sugar substitute, to medicaments containing these salts, and to the use of these salts for producing medicaments.
    Type: Grant
    Filed: November 14, 2011
    Date of Patent: December 25, 2018
    Assignee: GRUNENTHAL GMBH
    Inventors: Johannes Bartholomäus, Heinrich Kugelmann
  • Tamper-resistant dosage form containing one or more particles
    Patent number: 10154966
    Abstract: The invention relates to a tamper-resistant pharmaceutical dosage form comprising one or more particles, wherein each of said one or more particles comprises a pharmacologically active ingredient and a physiologically acceptable polymer; has a breaking strength of at least 300 N; has a weight of at least 2 mg; and optionally, comprises a film-coating; wherein the total weight of the pharmaceutical dosage form is greater than the total weight of said one or more particles.
    Type: Grant
    Filed: May 27, 2014
    Date of Patent: December 18, 2018
    Assignee: GRÜNENTHAL GMBH
    Inventors: Lutz Barnscheid, Anja Geiβler, Klaus Wening, Jana Pätz
  • CRYSTALLIZATION METHOD AND BIOAVAILABILITY
    Publication number: 20180333425
    Abstract: Preparation, in-vitro and in vivo characterization of novel forms of (1-hydroxy-2-imidazol-1-yl-1-phosphono-ethyl) phosphonic acid, suitable for pharmaceutical compositions in drug delivery systems for humans.
    Type: Application
    Filed: November 21, 2017
    Publication date: November 22, 2018
    Applicant: GRUNENTHAL GMBH
    Inventors: Mazen HANNA, Ning SHAN, Miranda L. CHENEY, David R. WEYNA, Raymond K. HOUCK
  • Abuse-proofed dosage form
    Patent number: 10130591
    Abstract: The present invention relates to an abuse-proofed, thermoformed dosage form containing, in addition to one or more active ingredients with abuse potential optionally together with physiologically acceptable auxiliary substances, at least one synthetic or natural polymer with a breaking strength of at least 500 N and to a process for the production thereof.
    Type: Grant
    Filed: September 14, 2016
    Date of Patent: November 20, 2018
    Assignee: GRÜNENTHAL GMBH
    Inventors: Johannes Bartholomäus, Heinrich Kugelmann, Elisabeth Arkenau-Marić
  • THERMOFORMED, TAMPER-RESISTANT PHARMACEUTICAL DOSAGE FORM CONTAINING ZINC
    Publication number: 20180326067
    Abstract: A thermoformed, tamper-resistant pharmaceutical dosage form comprises: a) a pharmacologically active ingredient; b) a polyalkylene oxide having a weight average molecular weight of more than 200,000 g/mol; and c) a zinc component, wherein the content of said zinc component is at least 1 ppm, relative to the total weight of the pharmaceutical dosage form. When the pharmacologically active ingredient is effective against pain, the pharmaceutical dosage form may be used in a method of treating pain. When the pharmacologically active ingredient has abuse potential, the pharmaceutical dosage form may be used in a method of reducing the incidence of the abuse of said pharmacologically active ingredient.
    Type: Application
    Filed: July 20, 2018
    Publication date: November 15, 2018
    Applicant: GRÜNENTHAL GMBH
    Inventors: LUTZ BARNSCHEID, ERIC GALIA, ANJA GEIßLER, JANA PÄTZ, SEBASTIAN SCHWIER, JULIA BARONSKY-PROBST
  • 3-((HETERO-)ARYL)-ALKYL-8-AMINO-2-OXO-1,3-DIAZA-SPIRO-[4.5]-DECANE DERIVATIVES
    Publication number: 20180327392
    Abstract: The invention relates to 3-((hetero-)aryl)-alkyl-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives, their preparation and their use in medicine, particularly in the treatment of pain.
    Type: Application
    Filed: May 21, 2018
    Publication date: November 15, 2018
    Applicant: GRÜNENTHAL GMBH
    Inventors: Sven KUEHNERT, Rene Michael KOENIGS, Achim KLESS, Anita WEGERT, Paul RATCLIFFE, Ruth JOSTOCK, Thomas KOCH, Klaus LINZ, Wolfgang SCHROEDER, Klaus SCHIENE, Ingo KONETZKI
  • ABUSE-PROOFED DOSAGE FORM
    Publication number: 20180318223
    Abstract: A solid administration form, protected from parenteral abuse and containing at least one viscosity-increasing agent in addition to one or more active substances that have parenteral abuse potential. The agent forms, when a necessary minimum amount of an aqueous liquid is added, on the basis of an extract obtained from the administration form, a preferably injectable gel that remains visually distinct when introduced into another quantity of an aqueous liquid.
    Type: Application
    Filed: July 11, 2018
    Publication date: November 8, 2018
    Applicant: GRÜNENTHAL GMBH
    Inventors: JOHANNES BARTHOLOMAEUS, HEINRICH KUGELMANN
  • Pyrazolyl substituted tetrahydropyranylsulfones
    Patent number: 10106530
    Abstract: The invention relates to pyrazolyl substituted tetrahydropyranylsulfones as voltage gated calcium channel blockers, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: October 23, 2018
    Assignee: GRÜNENTHAL GMBH
    Inventors: Stefan Schunk, Melanie Reich, René Michael Koenigs
  • Pyrazolyl substituted tetrahydropyranylsulfones
    Patent number: 10100041
    Abstract: The invention relates to pyrazolyl substituted tetrahydropyranylsulfones as voltage gated calcium channel blockers, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: October 16, 2018
    Assignee: GRÜNENTHAL GMBH
    Inventors: Stefan Schunk, Melanie Reich, René Michael Koenigs
  • Crystallization method and bioavailability
    Patent number: 10093691
    Abstract: Preparation and in vitro and in vivo characterization of novel forms of active pharmaceutical ingredients, suitable for pharmaceutical compositions in drug delivery systems for humans.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: October 9, 2018
    Assignee: GRUNENTHAL GMBH
    Inventors: Mazen Hanna, Ning Shan, Miranda L. Cheney, David R. Weyna, Raymond Houck
  • 8-AMINO-2-OXO-1,3-DIAZA-SPIRO-[4.5]-DECANE DERIVATIVES
    Publication number: 20180273516
    Abstract: The invention relates to 8-amino-2-oxo-1,3-diaza-spiro[4.5]-decane derivatives, their preparation and their use in medicine, particularly in the treatment of pain.
    Type: Application
    Filed: May 21, 2018
    Publication date: September 27, 2018
    Applicant: GRÜNENTHAL GMBH
    Inventors: Sven KUEHNERT, Rene Michael KOENIGS, Achim KLESS, Anita WEGERT, Paul RATCLIFFE, Ruth JOSTOCK, Thomas KOCH, Klaus LINZ, Wolfgang SCHROEDER
  • Method for the production of a form of administration of a medicament
    Patent number: 10080724
    Abstract: The present invention relates to a method for producing a medicament dosage form which consists of at least one piece which in each case comprises at least one medicament and at least one additive, the medicament and the additive being mixed and extruded from a die as a strand and the strand being cut into pieces of precise weight. The invention additionally relates to a device.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: September 25, 2018
    Assignee: GRÜNENTHAL GMBH
    Inventors: Elisabeth Arkenau-Marić, Johannes Bartholomäus, Dieter Schateikis, Kai-Uwe Ustorf
  • ABUSE-PROOFED DOSAGE FORM
    Publication number: 20180243237
    Abstract: The invention relates to a dosage form that is thermoshaped without being extruded and that is safeguarded from abuse, comprising at least one synthetic or natural polymer having a breaking strength of at least 500 N in addition to one or more active substances that could be subject to abuse and optionally physiologically acceptable adjuvants. The invention also relates to a corresponding method for producing said dosage form.
    Type: Application
    Filed: April 27, 2018
    Publication date: August 30, 2018
    Applicant: Grünenthal Gmbh
    Inventors: Elisabeth Arkenau-Maric, Johannes Bartholomaus, Heinrich Kugelmann
  • Abuse-proofed dosage form
    Patent number: 10058548
    Abstract: The invention relates to a dosage form that is thermoformed without discoloration and is safeguarded from abuse, comprising at least one synthetic or natural polymer having a breaking strength of at least 500 N in addition to one or more active substances that could be subject to abuse. The invention also relates to a corresponding method for producing said dosage form.
    Type: Grant
    Filed: March 15, 2017
    Date of Patent: August 28, 2018
    Assignee: GRÜNENTHAL GMBH
    Inventors: Elisabeth Arkenau-Maric, Johannes Bartholomaeus, Heinrich Kugelmann
  • ABUSE-PROOFED ORAL DOSAGE FORM
    Publication number: 20180235908
    Abstract: The present invention relates to an abuse-proofed oral dosage form with controlled release of (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol for once daily administration, which comprises the active ingredient and/or one or more of the pharmaceutically acceptable salts thereof (A), at least one synthetic or natural polymer (C), delayed-release auxiliary substances, optionally physiologically acceptable auxiliary substances (B) and optionally a wax (D), component (C) or (D) in each case exhibiting a breaking strength of at least 500 N, preferably of at least 1000 N.
    Type: Application
    Filed: April 19, 2018
    Publication date: August 23, 2018
    Applicant: GRÜNENTHAL GMBH
    Inventors: Johannes BARTHOLOMÄUS, Heinrich Kugelmann, Elisabeth Arkenau-Maric
  • TAMPER RESISTANT DOSAGE FORM WITH BIMODAL RELEASE PROFILE MANUFACTURED BY CO-EXTRUSION
    Publication number: 20180221307
    Abstract: The invention relates to a monolithic pharmaceutical dosage form comprising a hot melt-extruded first segment (S1) and a second segment (S2); wherein the first segment (S1) contains at least a first pharmacologically active ingredient (A1) and/or the second segment (S2) contains at least a second pharmacologically active ingredient (A2); and the segment (S1) and/or the segment (S2) is tamper-resistant and/or exhibits a breaking strength of at least 300 N.
    Type: Application
    Filed: January 30, 2018
    Publication date: August 9, 2018
    Applicant: GRÜNENTHAL GMBH
    Inventors: ANJA GEIßLER-FICHTNER, Klaus Wening, Lutz Barnscheid, Jana Pätz
  • Cebranopadol for treating pain in subjects with impaired hepatic and/or impaired renal function
    Patent number: 10022353
    Abstract: The invention relates to Cebranopadol or a physiologically acceptable salt thereof for use in the treatment or the prevention of pain and/or opioid drug dependence in a subject with impaired hepatic and/or renal function.
    Type: Grant
    Filed: January 22, 2016
    Date of Patent: July 17, 2018
    Assignee: GRÜNENTHAL GMBH
    Inventors: Elke Kleideiter, Annette Christoph, Rene Fussen, Joachim Ossig, Ramesh Boinpally